Abstract
In May and June 2020, an outbreak of methanol poisoning arose in the southwest United States linked to ingestion of contaminated hand sanitizer imported during the coronavirus disease 2019 pandemic, ultimately resulting in over a dozen hospitalizations and at least four deaths in New Mexico and Arizona. In this report, we describe one of these cases in which profound methanol intoxication was successfully treated with the Tablo® Hemodialysis System, the first reported case of toxic alcohol poisoning treated with this novel device. We carry out a formal regression analysis of the serial methanol levels obtained in this case to conservatively estimate that intermittent hemodialysis with Tablo achieved a clearance of methanol of 239 mL/min (95% confidence interval, 173–305 mL/min), a clearance that is well within the previously published standard of care. We conclude by reviewing both the treatment of toxic alcohol poisoning and the determinants of small molecule clearance with hemodialysis, emphasizing the importance of optimizing the dialytic treatment of intoxications with extended treatment times and the use of high-efficiency dialyzers.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Combs, Sara A. 2
; Shaffi, Saeed K. 2
; Xu, Zhi Q. 2 ; Aragon, Michael A. 3 ; Teixeira, J. Pedro 4
1 University of New Mexico School of Medicine, MSC10-5550, 1 University of New Mexico, Department of Internal Medicine, Albuquerque, USA (GRID:grid.266832.b) (ISNI:0000 0001 2188 8502)
2 University of New Mexico School of Medicine, MSC10-5550, 1 University of New Mexico, Department of Internal Medicine, Albuquerque, USA (GRID:grid.266832.b) (ISNI:0000 0001 2188 8502); University of New Mexico School of Medicine, MSC10-5550, 1 University of New Mexico, Division of Nephrology, Albuquerque, USA (GRID:grid.266832.b) (ISNI:0000 0001 2188 8502)
3 Outset Medical, San Jose, USA (GRID:grid.266832.b)
4 University of New Mexico School of Medicine, MSC10-5550, 1 University of New Mexico, Department of Internal Medicine, Albuquerque, USA (GRID:grid.266832.b) (ISNI:0000 0001 2188 8502); University of New Mexico School of Medicine, MSC10-5550, 1 University of New Mexico, Division of Nephrology, Albuquerque, USA (GRID:grid.266832.b) (ISNI:0000 0001 2188 8502); University of New Mexico School of Medicine, MSC10-5550, 1 University of New Mexico, Division of Pulmonary, Critical Care, & Sleep Medicine, Albuquerque, USA (GRID:grid.266832.b) (ISNI:0000 0001 2188 8502)




